Navigation Links
Trading Of Onyx Pharmaceuticals Common Stock Halted
Date:6/20/2012

SOUTH SAN FRANCISCO, Calif., June 20, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that NASDAQ has halted trading of the company's common stock.   The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) is meeting this afternoon to discuss the company's New Drug Application (NDA) for Kyprolis™ (proposed brand name for carfilzomib) under the accelerated approval pathway.

The NDA for Kyprolis for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies that included a proteasome inhibitor and an immunomodulatory agent is currently being reviewed by the U.S. FDA, and the anticipated date for completion of review under the PDUFA guidelines is July 27, 2012.

Conference Call Today
The Onyx management team will host a webcast and conference call to discuss the ODAC recommendation today at 7:00 p.m. Eastern Time (4:00 p.m. Pacific Time).

To access a live audio webcast of the conference call, log onto the company's website at: http://www.onyx.com/investors/event-calendar.

To access the live conference call, dial (847) 585-4405 and use the passcode 32594605. A replay of the call will be available on the Onyx website or by dialing (630) 652-3042 and using the passcode 3259 4605# approximately two hours after the conference call concludes through July 4, 2012.

About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx.com.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of Delisting Proceedings by NYSE
2. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
3. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
4. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
5. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
6. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
7. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
8. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
9. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
10. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
11. Valeant Pharmaceuticals To Host Investor Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/27/2020)... VICKSBURG, Miss. (PRWEB) , ... January 27, 2020 ... ... participated in Implant Seminars’ three-day intense hands-on experience with live patients in Santo ... the experienced guidance of Dr. Arun K. Garg. Drs. Nash routinely perform surgery ...
(Date:1/27/2020)... ... January 27, 2020 , ... ... telemedicine platform, the DirectVision® DVS-III Telehealth Hub, announced today it has partnered ... pilot program to provide clinical and emergency tele-urology services across the United ...
(Date:1/24/2020)... NEW YORK (PRWEB) , ... January 24, 2020 , ... ... the U.S. to implement a systematic reform of the health care system. Recently, practicing ... Doherty, Senior Vice President of Governmental Affairs and Public Policy at ACP, teamed with ...
Breaking Medicine Technology:
(Date:1/24/2020)... ... January 24, 2020 , ... ... the life sciences and food industries, is pleased to announce that Dr. Homa ... office and research site in Toronto, Canada. , Dr. Assadi’s extensive experience pertains ...
(Date:1/23/2020)... (PRWEB) , ... January 23, 2020 , ... A January ... and options to get rid of them. The article quotes the president of the ... a double-chin are many. They can be caused by a person’s facial structure including ...
(Date:1/23/2020)... ... ... Let’s face it; the holidays were a stressful time, a time when ... were revisited. It’s easy to understand why many folks prefer to duck out of ... holidays posed additional stress for which there is no “cookie-cutter” solution. , Dylan Walker, ...
(Date:1/23/2020)... YORK (PRWEB) , ... January 23, 2020 , ... Park ... his new website jschildhorn.com. Dr. Schildhorn is excited to bring this new digital portal ... graduate of Duke and attended medical school at Temple University. With over 12 years ...
(Date:1/23/2020)... Tenn. (PRWEB) , ... January ... ... top-rated patient engagement SaaS vendor announced their partner agreement with Healthpac, a ... third party billing offices and medical offices an expanded offering. Healthpac’s customers ...
Breaking Medicine News(10 mins):